Explore

Illume Fertility Details 12 Key Considerations for Egg Freezing Decisions

Illume Fertility Details 12 Key Considerations for Egg Freezing Decisions

Illume Fertility Details 12 Key Considerations for Egg Freezing Decisions

Johnson Johnson Announces Positive Phase 3 Results for ICOTYDE in Psoriatic Arthritis Treatment

Johnson Johnson Announces Positive Phase 3 Results for ICOTYDE in Psoriatic Arthritis Treatment

Johnson & Johnson has announced positive results from a Phase 3 investigational study for its drug ICOTYDE (icotrokinra) in treating biologic-naive adults with active psoriatic arthritis (PsA). The late-breaking data, presented at the American College of Rheumatology (ACR) Convergence 2026, showed that 58% of patients treated with ICOTYDE achieved an ACR20 response at Week 16, compared to 41% receiving a placebo. Furthermore, 29% achieved an ACR50 response. ICOTYDE is described as the first and only targeted oral peptide that precisely blocks the IL-23 receptor, a key driver of inflammation in psoriatic diseases. The study also reported significant improvements in skin involvement, with 57% of patients achieving clear or almost clear skin (Investigator's Global Assessment 0/1) and 37% achieving a Psoriasis Area and Severity Index (PASI) score of 90, compared to placebo groups. Safety findings were consistent with the established safety profile of ICOTYDE, with no new safety signals identified through Week ...

Menopur Market Sees Growth Driven by Rising Infertility Rates and Healthcare Spending

Menopur Market Sees Growth Driven by Rising Infertility Rates and Healthcare Spending

Menopur Market Sees Growth Driven by Rising Infertility Rates and Healthcare Spending

Healthspan Summit 2026 to Convene Longevity Medicine and Clinical Innovation Leaders in Los Angeles

Healthspan Summit 2026 to Convene Longevity Medicine and Clinical Innovation Leaders in Los Angeles

The fourth annual Healthspan Summit is scheduled to take place over two days in Los Angeles, serving as a key business meeting for the clinical longevity sector in the United States. The summit is structured around three main tracks: Longevity Medicine and Clinical Innovation, Aesthetic Innovation / Beautyspan, and Fitness, Recovery and Human Performance. The Longevity Medicine track will cover diagnostics, biological-age testing, geroprotective protocols, hormone and metabolic optimization, and strategies for clinics to build evidence-based service lines. The event is specifically designed as a business-to-business gathering, targeting clinicians, medical directors, founders, operators, and investors rather than a general consumer audience. It aims to provide insights into how to structure, price, and defend claims for longevity services.

AI Integration in Clinical Trials Shows Early Efficiency Gains, Faces Scaling Challenges

AI Integration in Clinical Trials Shows Early Efficiency Gains, Faces Scaling Challenges

AI Integration in Clinical Trials Shows Early Efficiency Gains, Faces Scaling Challenges

Moderna Reports Q3 2026 Profit, Signaling Shift from Consistent Losses

Moderna Reports Q3 2026 Profit, Signaling Shift from Consistent Losses

Moderna Reports Q3 2026 Profit, Signaling Shift from Consistent Losses

MHRA Issues New Guidance on Non-OECD Clinical Trial Data Assessment to Support UK Research

MHRA Issues New Guidance on Non-OECD Clinical Trial Data Assessment to Support UK Research

The Medicines and Healthcare products Regulatory Agency (MHRA) has published new guidance detailing its patient-centered approach to assessing clinical trial applications that rely on non-clinical safety data generated outside the Organisation for Economic Co-operation and Development (OECD) Mutual Acceptance of Data framework. This guidance, issued on November 4, 2026, aims to support a more risk-proportionate approach to clinical research, thereby advancing the development of new treatments and increasing opportunities for UK patients to participate in trials. While data generated within the OECD framework remains the expected standard, the MHRA will now consider non-OECD data in individual applications, particularly when supported by evidence and the circumstances of the intended patient population.

FDA Approves Two Gene Therapies for Inherited Immune Disorders, Highlighting Access Challenges

FDA Approves Two Gene Therapies for Inherited Immune Disorders, Highlighting Access Challenges

Within the past year, the FDA has approved two gene therapies for inherited immune disorders: etuvetidigene autotemcel (etu-cel, Waskyra) for Wiskott-Aldrich syndrome (WAS) and Exagamglogene autotemcel (Casgevy) for sickle cell disease and transfusion-dependent β-thalassemia. Etu-cel, approved in December 2025, is for WAS patients aged 6 months and older who are eligible for hematopoietic stem cell transplantation but lack a suitable donor. Casgevy's eligibility was expanded in July 2026 to include patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent β-thalassemia, lowering the previous age threshold. While these approvals offer new treatment options, experts at the 2026 American Society for Transplantation and Cellular Therapy Gene Therapy Summit emphasized ongoing challenges in manufacturing quality, long-term safety, and patient access. For instance, Casgevy's label requires lifelong malignancy surveillance and regular blood counts, highli...

Pharmacogenomics Market Projected to Reach $15.98 Billion by 2030 Driven by AI and Precision Medicine

Pharmacogenomics Market Projected to Reach $15.98 Billion by 2030 Driven by AI and Precision Medicine

The pharmacogenomics market is experiencing rapid growth, with projections indicating it will reach $15.98 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.2%. This expansion is fueled by increasing investments in precision medicine, the growing adoption of AI-powered genomic analysis, and broader applications in oncology and cardiology. Key trends shaping the industry include personalized medicine adoption, genetic testing for drug selection, integration of pharmacogenomic data into clinical workflows, and the expansion of companion diagnostics. Major companies in this landscape include Illumina Inc, Eurofins Scientific, Myriad Genetics Inc, and Thermo Fisher Scientific Inc. Recent strategic moves, such as Genomenon's acquisition of Boston Genetics in June 2023, aim to enhance genomic intelligence capabilities by merging AI platforms with expert genome curation. Innovations like PGxAI's Sirius model, launched in December 2024, are further transforming drug response prediction and man...

Onchilles Pharma Reports Promising Early Clinical Data for N17350, a Personalized Cancer Vaccine Approach

Onchilles Pharma Reports Promising Early Clinical Data for N17350, a Personalized Cancer Vaccine Approach

Onchilles Pharma, a clinical-stage biotechnology company, has reported initial clinical findings from its Phase 1/2 trial (OP-NEU-101) of intratumoral N17350 in patients with advanced solid tumors. The data, presented at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), suggest that N17350 could effectively turn an injected tumor into a personalized cancer vaccine without requiring tumor sequencing or custom manufacturing. N17350 is an engineered therapeutic elastase derived from a cancer-killing enzyme found in human neutrophils. When injected into a tumor, it selectively kills cancer cells and releases the tumor's own antigens, thereby training the immune system to attack cancer elsewhere in the body. In the first dose cohort, three heavily pretreated patients showed no dose-limiting toxicities. Notably, a patient with Merkel cell carcinoma experienced the disappearance of five non-injected lesions after N17350 was injected into a single lesion, indicating systemic immune activat...

Agenus Reports Strong Third Quarter 2026 Results and Advances Phase 3 ROBBIN Study for Colon Cancer

Agenus Reports Strong Third Quarter 2026 Results and Advances Phase 3 ROBBIN Study for Colon Cancer

Agenus Reports Strong Third Quarter 2026 Results and Advances Phase 3 ROBBIN Study for Colon Cancer

Senate HELP Committee Proposes AI in Healthcare Act; CMS Finalizes New Organ Procurement Rules

Senate HELP Committee Proposes AI in Healthcare Act; CMS Finalizes New Organ Procurement Rules

Senator Bill Cassidy (R-LA), Chairman of the Senate Health, Education, Labor and Pensions (HELP) Committee, has introduced a legislative discussion draft for the 'Protecting Americans Through Intelligent, Ethical, and Transparent (PATIENT) Artificial Intelligence in Health Care Act.' This proposal aims to direct the Department of Health and Human Services (HHS) to issue guidance on patient privacy in AI, clarify oversight responsibilities for AI-based technology between the Food and Drug Administration (FDA) and the Office of the National Coordinator for Health Information Technology (ONC), grant the FDA new review authority, and establish a payment pathway for AI tool adoption. Stakeholder feedback on this draft is due by December 1, 2026. Concurrently, the Centers for Medicare & Medicaid Services (CMS) has finalized new rules for Organ Procurement Organizations (OPOs) to enhance organ donation and strengthen accountability, including clearer requirements for OPO transitions, improved oversight of medical...